# Semaglutide and Vascular Regeneration

> **NCT05870462** · PHASE4 · UNKNOWN · sponsor: **Canadian Medical and Surgical Knowledge Translation Research Group** · enrollment: 100 (estimated)

## Conditions studied

- Atherosclerosis
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Obesity

## Interventions

- **DRUG:** Semaglutide Pen Injector

## Key facts

- **NCT ID:** NCT05870462
- **Lead sponsor:** Canadian Medical and Surgical Knowledge Translation Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-29
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-07-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05870462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05870462, "Semaglutide and Vascular Regeneration". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05870462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*